Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

Exclusion Criteria

• •Any prior receipt of oxaliplatin or fluoropyrimidine chemotherapy (other than radiation-sensitizing fluoropyrimidine chemotherapy)
• •Prior receipt of systemic chemotherapy in the 6 months prior to Day 1 of Cycle 1 of FOX (other than radiation-sensitizing chemotherapy)
• •Known mismatch repair deficiency or microsatellite instability-high disease
• •Known dihydropyrimidine dehydrogenase (DPD) deficiency, as identified by clinically indicated screening
• •Any confirmed second malignancy that is likely to require systemic therapy during the course of the six-month study period, in the opinion of the enrolling investigator
• •Any of the following baseline laboratory abnormalities:
• •* Absolute neutrophil count (ANC) \< 2,500/mm3
• •* Platelet count \< 100,000/mm3
• •* Hemoglobin \< 9 g/dL
• •* Creatinine \> 1.5 x ULN
• •* Total bilirubin \> 1.5 x ULN
• •* AST/ALT \> 5 x ULN
• •* Patients who are unable to provide informed consent
• •* Patients who are pregnant or breastfeeding
• •* Patients who are incarcerated, homeless, or have active substance use disorders